This shareable PDF can be hosted on any platform or network and is fully compliant with publisher copyright.
This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.
If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.
This page is a summary of: Cost of achieving HbA1c and weight loss treatment targets with IDegLira vs insulin glargine U100 plus insulin aspart in the USA, ClinicoEconomics and Outcomes Research, March 2019, Dove Medical Press,
DOI: 10.2147/ceor.s194719.
You can read the full text:
The following have contributed to this page
